At a glance
- Originator Alcon
- Class Eye disorder therapies
- Mechanism of Action Glutathione peroxidase stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cataracts
Most Recent Events
- 19 Jan 1998 No-Development-Reported for Cataracts in USA (Unknown route)
- 26 Oct 1994 Preclinical development for Cataracts in USA (Unknown route)